Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease | Zendy

Lon S. Schneider | Zendy; Pierre N. Tariot | Zendy; Karen Dagerman | Zendy; Sonia M. Davis | Zendy; John Hsiao | Zendy; M. Saleem Ismail | Zendy; Barry D. Lebowitz | Zendy; Constantine G. Lyketsos | Zendy; J. Michael Ryan | Zendy; T. Scott Stroup | Zendy; David L. Sultzer | Zendy; Daniel Weintraub | Zendy; Jeffrey A. Lieberman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease

Author(s) -

Lon S. Schneider,

Pierre N. Tariot,

Karen Dagerman,

Sonia M. Davis,

John Hsiao,

M. Saleem Ismail,

Barry D. Lebowitz,

Constantine G. Lyketsos,

J. Michael Ryan,

T. Scott Stroup,

David L. Sultzer,

Daniel Weintraub,

Jeffrey A. Lieberman

Publication year - 2006

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa061240

Subject(s) - olanzapine , discontinuation , quetiapine , risperidone , medicine , placebo , antipsychotic , atypical antipsychotic , extrapyramidal symptoms , clinical global impression , adverse effect , psychiatry , schizophrenia (object oriented programming) , alternative medicine , pathology

Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research